Relatlimab (also known as lemzoparlimab) is a monoclonal antibody that is being investigated for the treatment of various forms of cancer. It is designed to target and bind to a protein called programmed cell death 1 (PD-1) which is found on the surface of certain immune cells. By blocking the PD-1 protein, Relatlimab is thought to promote an anti-tumor immune response by allowing the immune system to recognize and fight off cancer cells. Currently, Relatlimab is being investigated in clinical trials for the treatment of advanced solid tumors, non-small cell lung cancer, and Hodgkin lymphoma.
Relatlimab is an investigational medication, meaning it's still under development and not yet commercially available or approved for any medical use. Here's what we know so far about Relatlimab:
- Potential Use: Relatlimab is being studied as a potential treatment for various cancers, including:
- Melanoma: A type of skin cancer that can spread to other parts of the body [1].
- Non-small cell lung cancer (NSCLC): A common type of lung cancer [2].
- Other solid tumors: Early-stage clinical trials are also investigating Relatlimab for other types of solid tumors [3].
- How it Might Work: Relatlimab belongs to a class of drugs called programmed cell death protein-1 (PD-1) inhibitors, also known as immune checkpoint inhibitors [1, 2, 3]. These medications work by targeting a molecule called PD-1, which is found on immune cells (T cells) and can act as a brake on the immune system. By blocking PD-1, Relatlimab helps T cells recognize and attack cancer cells more effectively [1, 2, 3].
- Current Stage: Relatlimab is undergoing clinical trials to assess its safety, efficacy (how well it works), and ideal dosage for different cancer types [1, 2, 3].
- Important Considerations:
- Since it's investigational, Relatlimab is not available for prescription or to treat any cancer type outside of clinical trials.
- More research is needed to determine its effectiveness and safety profile compared to existing cancer treatments.
- If you have cancer, consult with a doctor regarding established treatment options. Self-treating with investigational drugs is not recommended and can be dangerous.